对于部分cNDI引起的V2R突变体,非性V2R激活剂的治疗潜力
Ritsuki Kuramoto1, Ryoji Kise1, Mayu Kanno1
1Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan.
PloS one
|May 15, 2024
概括
新的非类V2R激动剂,如OPC-51803,显示出治疗先天性原性糖尿病无味症 (cNDI) 的前景. 这些化合物恢复V2R突变的功能,为部分cNDI患者提供潜在的治疗策略.
科学领域:
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 2型血管压素受体 (V2R) 的功能丧失突变会导致先天性原性糖尿病无味症 (cNDI).
- 部分cNDI涉及减少但不缺席对德斯莫普雷辛 (dDAVP) 的反应.
- 恢复V2R功能是部分cNDI的潜在治疗目标.
研究的目的:
- 研究OPC-51803和相关激动剂在与部分cNDI相关的V2R突变体中恢复功能的潜力.
- 评估这些新型激动剂的信号配置,包括Gs-cAMP和β-arrestin的招募.
主要方法:
- 评估了OPC-51803和相关化合物的能力,以恢复六个部分V2R突变的功能.
- 测量了cAMP响应和经过长时间的激动剂刺激后的β-停止剂招募.
- 利用对接分析来了解激素激剂-受体相互作用.
主要成果:
- OPC-51803和相关激动剂功能恢复了V2R突变体,诱导了长时间的信号激活.
- 这些激动剂表现出功能选择性,激活Gs-cAMP通路而不招募β-arrestin.
- 在长时间刺激后,一些激动剂在V2R突变体中引起了比AVP更大的cAMP反应.
- 对接分析表明,由于激动剂与L3127.40的相互作用,改变了TM7协调,这有助于功能选择性.
结论:
- 非类V2R激动剂,如OPC-51803,可以恢复V2R突变的功能,导致部分cNDI.
- 这些激动剂表现出功能选择性,有利于Gs-cAMP信号传递.
- 新型非类V2R激动剂代表了治疗部分cNDI的有希望的药物候选者.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
159
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
159
Direct-Acting Cholinergic Agonists: Therapeutic Uses
731
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
731
Drug-Receptor Interaction: Agonist
2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
1.8K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.8K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
674
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
674
Adrenergic Agonists: Indirect-Acting Agents
1.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.6K


